Reports On Efforts To Quickly Develop Swine Flu Vaccine
Posted on: Wednesday, 3 June 2009, 08:18 CDT
Scientists around the world are accelerating their efforts to develop a vaccine against the H1N1 influenza virus (Swine flu) as rapidly as possible, reports Genetic Engineering & Biotechnology News (GEN). The need for such a vaccine received a strong impetus from the World Health Organization, which has issued a Phase 5 pandemic alert, a strong signal that the WHO believes a pandemic is imminent, according to the June 1 issue of GEN (www.genengnews.com/articles/chitem.aspx?aid=2938)."It can take five or six months to come up with an entirely novel influenza vaccine," says John Sterling, Editor in Chief of GEN . "There is a great deal of hope that biotech and pharma companies might be able to have something ready sooner."
One company, Replikins, actually predicted over a year ago that significant outbreaks of the H1N1 flu virus would occur within 6-12 months. The predictions were based on correlations of flu virus specimens and PubMed documentation of major outbreaks during the past 90 years, focusing on concentrations of, and spacings between, replikins—the lysine and histidine residues in the hemagglutinin (HA) unit genetic sequences of the eight major genes in the influenza virus. Replikins' officials say the company's PanFLu™ vaccine is ready for clinical trials.
Novavax plans to create a virus-like particle-based (VLP) vaccine against the H1N1 strain, which obviates the need for a live virus seed for manufacturing. The VLPs contain the proteins that make the virus' outer shell and the surface proteins, without the RNA required for replication.
------------
On The Net:
Mary Ann Liebert, Inc./Genetic Engineering News
Related Articles
- Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza
- First Swine Flu Genetic Sequencing Complete
- Novartis Ships Influenza Virus Vaccines to US
- Novartis Begins Shipment to US of Fluvirin(R) Influenza Virus Vaccine With Three New Strains for the 2008-2009 Influenza Season
- Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customers
- Sanofi Pasteur Donates 200,000 Doses of Fluzone(R), Influenza Virus Vaccine to Support Government's Hurricane Relief Efforts
- Medimmune Awarded Contract for Influenza Virus Vaccine
- Chiron Will Not Supply BEGRIVAC(TM) Influenza Virus Vaccine to Non-U.S. Markets
- Chiron Reduces Supply Expectations for BEGRIVAC(TM) Influenza Virus Vaccine to Non-U.S. Markets
- FDA On-Site Inspection of Chiron's FLUVIRIN(R) Influenza Virus Vaccine Facility Underway
Rating: 2.5 / 5 (8 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds